Acute Kidney Injury takes place if the kidneys stop the filtration of the waste products from human blood. There are 25+ companies involved in the development of novel therapies for the treatment of acute kidney injury. The key players operating in the Acute Kidney Injury treatment market include Atox Bio, AM-Pharma, Angion Biomedica, Astellas Pharma, Guard therapeutics and several others.
DelveInsight’s ‘Acute Kidney Injury Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Acute Kidney Injury therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Kidney Injury pipeline domain.
Key Takeaways from the Acute Kidney Injury Pipeline Report
Request a sample and discover the recent breakthroughs happening Acute Kidney Injury pipeline landscape in @ Acute Kidney Injury Pipeline Outlook
The Acute Kidney Injury pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acute Kidney Injury products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acute Kidney Injury pipeline landscape.
Acute Kidney Injury Overview
Acute Kidney Injury (AKI), commonly known as Acute Renal Failure (ARF), is a condition characterised by progressive azotemia with or without oliguria over several hours or days. Acute Kidney Injury is typically characterised as a sudden loss in renal function, clinically manifested as a reversible acute rise in nitrogen waste products evaluated by blood urea nitrogen and serum creatinine levels over hours to weeks. Acute Kidney Injury causes a sudden decrease in renal function, resulting in waste product retention, electrolyte abnormalities, and volume status changes. There are three Acute Kidney Injury stages: prerenal, postrenal, and intrinsic renal.
Many people with Acute Kidney Injury are asymptomatic, while others have generalised non-specific Acute Kidney Injury symptoms such as nausea, vomiting, weakness, dizziness, lower back pain, passing less urine than usual, unexplained loss of appetite, feeling sick or vomiting, feeling short of breath, and swelling of the legs or other body parts.
Acute Kidney Injury diagnosis is generally based on an increase in serum creatinine and/or a decrease in urine output.
Find out more about Acute Kidney Injury medications @ Acute Kidney Injury Guidelines
A snapshot of the Acute Kidney Injury Pipeline Drugs mentioned in the report:
Drugs
Company
Phase
MoA
RoA
ANG-3777
Angion Biomedica/Vifor Pharma
Phase II
Proto oncogene protein c met stimulant
Intravenous
Ilofotase alfa
AM Pharma
Phase III
Endotoxin inhibitors; Enzyme replacements
NA
ASP1128
Astellas Pharma
Peroxisome proliferator-activated receptor delta modulators
Ruconest (Conestat alfa)
Pharming Technologies
Complement C1 inhibitor protein replacements; Complement C1r inhibitors; Complement C1s inhibitors
RMC-035
Guard Therapeutics
Alpha 1 microglobulin replacements
SBI-101
Sentien Biotechnologies
Phase I/II
Stem cell modulators
Parenteral
Timbetasin
RegeneRx Biopharmaceuticals
Preclinical
Actin modulators; Amyloid inhibitors
Acute Kidney Injury Therapeutics Assessment
The Acute Kidney Injury Pipeline report proffers an integral view of the Acute Kidney Injury emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Acute Kidney Injury Pipeline Report
Dive deep into rich insights for drugs for Acute Kidney Injury, visit @ Acute Kidney Injury Emerging Therapies
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Acute Kidney Injury Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Acute Kidney Injury Pipeline Therapeutics
6.
Acute Kidney Injury Pipeline: Late Stage Products (Phase III)
6.1
Ilofotase alfa: AM-Pharma
7.
8.
Acute Kidney Injury Pipeline: Mid Stage Products (Phase II)
8.1
ANG-3777: ANG-3777
9.
Acute Kidney Injury Pipeline: Early Stage Products (Phase I)
9.1
RBT-9: Renibus Therapeutics
10.
Therapeutic Assessment
11.
Inactive Products
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Companies
14.
Key Products
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on the Acute Kidney Injury pipeline therapeutics, reach out@ Drugs for Acute Kidney Injury
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight